Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-501 ECT for Glaucoma
NCT02862938Phase 2Active, not recruiting
- Sponsor
- Stanford University
- Start
- Jun 2016
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ciliary neurotrophic factor in Glaucoma, sponsored by Stanford University. Started Jun 2016; status: active, not recruiting.
02
Drugs
ciliary neurotrophic factor
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT02862938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862938.